Cochlear (FRA:OC5) Research & Development: €170 Mil (TTM As of Dec. 2025)


FRA:OC5 Cochlear Ltd FRA:OC5
75 GF Score
Price €70.64
GF Value €185.38
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Cochlear Research & Development?

Cochlear FRA:OC5 +3.02% 75 Research & Development is €170 Mil as of Dec. 2025. GuruFocus rates FRA:OC5 with a GF Score™ of 75/100 and a GF Value™ of €185.38 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cochlear's Research & Development for the six months ended in Dec. 2025 was €87 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €170 Mil.

Cochlear  (FRA:OC5) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cochlear Research & Development Related Terms

Cochlear Research & Development Historical Data

* Premium members only.

The historical data trend for Cochlear's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cochlear Research & Development Chart

Cochlear Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.74 140.07 151.71 170.87 164.54

Cochlear Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.14 92.35 87.34 83.03 86.71
FRA:OC5
75GF Score
Cochlear Ltd FRA:OC5
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cochlear Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €170 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €170 Mil mean?
Cochlear (FRA:OC5) has a Research & Development of €170 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Cochlear and its competitors.
Is Cochlear's Research & Development too high?
Cochlear's current Research & Development is €170 Mil. Overall, Cochlear has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cochlear's Research & Development compare to ABT and SYK?
Cochlear's Research & Development of €170 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cochlear and its competitors. Cochlear's current Research & Development is €170 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cochlear stock overvalued right now?
Based on GuruFocus' analysis, Cochlear (FRA:OC5) is currently considered Significantly Undervalued. The stock's GF Value™ is €185.38, compared to a current price of €70.64 — trading 61.9% below its estimated fair value. The current Research & Development is €170 Mil. Cochlear's overall GF Score™ is 75/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cochlear (FRA:OC5), the current Research & Development is €170 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cochlear (FRA:OC5) Overvalued in 2026?

Based on GuruFocus' analysis, Cochlear stock appears to be undervalued. The current stock price of €70.64 is trading 61.9% below its estimated GF Value™ of €185.38. GuruFocus considers Cochlear to be Significantly Undervalued.

Key valuation signals for FRA:OC5:

  • Research & Development: €170 Mil
  • GF Value™: €185.38 vs. price of €70.64 (61.9% below fair value)
  • GF Score™: 75/100 with 2 warning signs

No single metric tells the full story. See the FRA:OC5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cochlear Business Description

Address 1 University Avenue, Macquarie University, Sydney, NSW, AUS, 2109
Cochlear is the leading cochlear implant device manufacturer, with around 60% global market share. Developed markets contribute 80% of group revenue, where cochlear implants are the standard of care for children with severe-to-profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
75GF Score

Get the complete analysis for FRA:OC5

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.64
Price
€185.38
GF Value